A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that blocking two proteins can halt and even reverse lung scarring in ...
The pulmonary fibrosis treatment market could grow from $1.3 billion to $2.7 billion by 2035 as newer therapies aim to ...
A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that blocking two proteins can halt and even reverse lung scarring in ...
Duke-NUS researchers have identified that blocking specific proteins in immune cells can significantly reduce or reverse lung scarring. This discovery paves the way for novel treatments that could ...
Researchers led by Virginia Tech have found that inhibiting proteins ID1 and ID3 can halt and even reverse lung scarring in pre-clinical models of idiopathic pulmonary fibrosis. The approach improved ...
A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that blocking two proteins can halt and even reverse lung scarring in ...
Add Yahoo as a preferred source to see more of our stories on Google. Many respiratory viral infections can cause long-term symptoms. sbk_20d pictures/Moment via Getty Images The long-term effects of ...
"This work demonstrates the power of spatial transcriptomics combined with data science approaches in unraveling the molecular etiology of long COVID." The researchers note that the findings could ...
A cancer drug available on the NHS could treat an incurable lung disease that plagues more than 30,000 Britons, a study claims. Idiopathic pulmonary fibrosis (IPF) occurs when scar tissue builds up in ...
Virginia Tech scientists at the Fralin Biomedical Research Institute at VTC study ways to reverse lung scarring in pulmonary fibrosis. Assistant Professor Yassine Sassi (from left), postdoctoral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results